Hemlibra (emicizumab-kxwh) safely supports joint health in children with hemophilia A without inhibitors through three years ...

Columnist Jennifer Lynne talks to Connie Montgomery, who has factor VII deficiency, about her advocacy for women with bleeding disorders.

MacDonald reflects on how much hemophilia care has changed and reminds her how much she has to be thankful for.

Many women with hemophilia grew up being taught to downplay their symptoms, writes columnist. That is the wrong approach.

Caregiving cuts both ways, writes columnist Allyx Formalejo this Family Caregivers Month, and not all care flows in the ...

Columnist Jennifer Lynne reflects on a powerful event that kicked off this year's Hope Conference in Orlando, Florida.

Geneventiv said the FDA had "positive" feedback in a meeting on developing GENV-HEM, the company's gene therapy for ...

Inhibitors are one of the most severe complications of hemophilia. Caeleb’s complications didn’t stop with that diagnosis. He had at least eight ports, as they would become infected or break. Daily ...

Columnist G Shellye Horowitz writes that postponing factor infusions may be tempting, but prophylaxis is better than a bleed.

Columnist Allyx Formalejo reminds readers this National Epilepsy Awareness Month that some stories about epilepsy begin with ...

Healing takes time, writes columnist Jennifer Lynne, who has come to believe that there’s wisdom in slowing down in all things.

Biomarin Pharmaceutical is looking to sell off rights to Roctavian, its approved gene therapy for hemophilia A.